Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


10.1111/febs.15369

http://scihub22266oqcxt.onion/10.1111/febs.15369
suck pdf from google scholar
32428379!7276759!32428379
unlimited free pdf from europmc32428379    free
PDF from PMC    free
html from PMC    free

suck abstract from ncbi


Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534

Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
pmid32428379      FEBS+J 2020 ; 287 (17): 3664-3671
Nephropedia Template TP

gab.com Text

Twit Text FOAVip

Twit Text #

English Wikipedia


  • Understanding SARS-CoV-2 endocytosis for COVID-19 drug repurposing #MMPMID32428379
  • Glebov OO
  • FEBS J 2020[Sep]; 287 (17): 3664-3671 PMID32428379show ga
  • The quest for the effective treatment against coronavirus disease 2019 pneumonia caused by the severe acute respiratory syndrome (SARS)-coronavirus 2(CoV-2) coronavirus is hampered by the lack of knowledge concerning the basic cell biology of the infection. Given that most viruses use endocytosis to enter the host cell, mechanistic investigation of SARS-CoV-2 infection needs to consider the diversity of endocytic pathways available for SARS-CoV-2 entry in the human lung epithelium. Taking advantage of the well-established methodology of membrane trafficking studies, this research direction allows for the rapid characterisation of the key cell biological mechanism(s) responsible for SARS-CoV-2 infection. Furthermore, 11 clinically approved generic drugs are identified as potential candidates for repurposing as blockers of several potential routes for SARS-CoV-2 endocytosis. More broadly, the paradigm of targeting a fundamental aspect of human cell biology to protect against infection may be advantageous in the context of future pandemic outbreaks.
  • |*COVID-19 Drug Treatment[MESH]
  • |*Drug Repositioning[MESH]
  • |Alveolar Epithelial Cells/drug effects/virology[MESH]
  • |Amiloride/pharmacology[MESH]
  • |Antiviral Agents/*pharmacology[MESH]
  • |COVID-19/metabolism/pathology/virology[MESH]
  • |Caveolae/drug effects/virology[MESH]
  • |Chlorpromazine/pharmacology[MESH]
  • |Clathrin-Coated Vesicles/drug effects/virology[MESH]
  • |Endocytosis/*drug effects[MESH]
  • |Endosomes/drug effects/virology[MESH]
  • |Humans[MESH]
  • |Itraconazole/pharmacology[MESH]
  • |Lung/drug effects/metabolism/pathology/virology[MESH]
  • |Lysosomes/drug effects/virology[MESH]
  • |Nystatin/pharmacology[MESH]
  • |Pinocytosis/drug effects[MESH]
  • |SARS-CoV-2/*drug effects/metabolism/pathogenicity[MESH]
  • |Vinblastine/pharmacology[MESH]


  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    Linkout box